John N Galgiani Selected Research

Coccidioidomycosis

10/2022	FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.
3/2022	Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity.
12/2021	Natural History of Disseminated Coccidioidomycosis: Examination of the Veterans Affairs-Armed Forces Database.
11/2021	Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis.
11/2021	Comparison of a Novel Rapid Lateral Flow Assay to Enzyme Immunoassay Results for Early Diagnosis of Coccidioidomycosis.
1/2021	TNFα Blockade Inhibits Both Initial and Continued Control of Pulmonary Coccidioides.
1/2021	Vaccine Protection of Mice With Primary Immunodeficiencies Against Disseminated Coccidioidomycosis.
1/2021	A quantitative enzyme-linked immunoassay (ELISA) to approximate complement-fixing antibody titers in serum from patients with coccidioidomycosis.
1/2019	Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA.
1/2019	The Rise of Coccidioides: Forces Against the Dust Devil Unleashed.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John N Galgiani Research Topics

Disease

30	Coccidioidomycosis 10/2022 - 10/2002
19	Infections 01/2022 - 06/2002
3	Mycoses (Diseases, Fungus) 01/2018 - 04/2008
1	Central Nervous System Infections (Central Nervous System Infection) 09/2022
1	Autoimmune Diseases (Autoimmune Disease) 03/2022
1	Injection Site Reaction 11/2021
1	Persistent Infection 10/2021
1	Convalescence 01/2020
1	Necrosis 01/2020
1	Intractable Pain 01/2015
1	Neurologic Manifestations (Neurological Manifestations) 01/2015
1	Disease Progression 01/2015
1	Chronic Mucocutaneous Candidiasis 06/2013
1	Histoplasmosis 06/2013
1	Rheumatic Diseases (Rheumatism) 12/2012

Drug/Important Bio-Agent (IBA)

9	VaccinesIBA 11/2021 - 03/2006
7	AntigensIBA 01/2022 - 06/2002
3	Pharmaceutical PreparationsIBA 10/2022 - 01/2019
3	Interleukin-12 (IL 12)IBA 01/2017 - 09/2009
3	nikkomycinIBA 06/2014 - 09/2007
2	Biological ProductsIBA 03/2022 - 12/2012
2	EnzymesIBA 11/2021 - 01/2021
2	Complement System Proteins (Complement)IBA 11/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 10/2021 - 07/2006
2	CytokinesIBA 01/2021 - 01/2021
1	ProcalcitoninIBA 11/2021
1	MetalsIBA 10/2021
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 10/2021
1	ZincIBA 10/2021
1	CopperIBA 10/2021
1	IronIBA 10/2021
1	LactoferrinIBA 10/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	AntibodiesIBA 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	GlucansIBA 11/2018
1	ChitinIBA 11/2018
1	InterferonsIBA 01/2017
1	VT-1161IBA 12/2015
1	Fluconazole (Zonal)FDA LinkGeneric 12/2015
1	Chitin SynthaseIBA 06/2014
1	STAT1 Transcription FactorIBA 06/2013
1	Antirheumatic Agents (DMARD)IBA 12/2012
1	Interleukin-12 Receptors (Interleukin 12 Receptor)IBA 02/2011
1	Interferon-gamma (Interferon, gamma)IBA 09/2009
1	AzolesIBA 09/2007
1	posaconazole FDA Link 09/2007
1	PyransIBA 10/2006
1	ambruticin SIBA 10/2006
1	ambruticinIBA 10/2006
1	AcidsIBA 10/2006
1	Proline (L-Proline)FDA Link 07/2002

Therapy/Procedure

10	Therapeutics 09/2022 - 10/2002
1	Debridement 01/2015
1	Organ Transplantation 07/2013